tradingkey.logo

GlucoTrack Inc

GCTK
查看詳細走勢圖
1.740USD
+0.190+12.26%
收盤 02/06, 16:00美東報價延遲15分鐘
1.56M總市值
虧損本益比TTM

GlucoTrack Inc

1.740
+0.190+12.26%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+12.26%

5天

-8.90%

1月

-56.28%

6月

-70.05%

今年開始到現在

-55.04%

1年

-95.49%

查看詳細走勢圖

TradingKey GlucoTrack Inc股票評分

單位: USD 更新時間: 2026-02-06

操作建議

GlucoTrack Inc當前公司基本面數據相對非常健康,最新ESG揭露屬於行業領先水平。增長潛力很大。當前估值合理,在生物技術與醫療研究行業排名225/392位。機構持股佔比很高,中期看,股價處於下降通道。近一個月,市場表現非常差,但基本面評分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

GlucoTrack Inc評分

相關信息

行業排名
225 / 392
全市場排名
470 / 4521
所屬行業
生物技術與醫療研究

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

公司輿情

過去24小時
熱度

過冷
過熱
中性

GlucoTrack Inc亮點

亮點風險
Glucotrack, Inc. is focused on the design, development, and commercialization of technologies for people with diabetes. The Company is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. It has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The Company has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety.
利潤高增長
公司淨利潤處於行業前列,最新年度總收入0.00美元
估值高估
公司最新PE估值-0.00,處於3年歷史高位
詹姆斯·西蒙斯持倉
明星投資者詹姆斯·西蒙斯持倉,最新持倉0.00股

分析師目標

基於 0 分析師
--
評級
--
目標均價
--
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

GlucoTrack Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

GlucoTrack Inc簡介

Glucotrack, Inc. is focused on the design, development, and commercialization of technologies for people with diabetes. The Company is engaged in developing a long-term Implantable Continuous Blood Glucose Monitor (CBGM) for people living with Type 1 diabetes and insulin-dependent Type 2 diabetes. Its CBGM is a long-term, implantable system that continually measures blood glucose levels with a sensor longevity of 3 years, no on-body wearable component and with minimal calibration. Its CBGM technology allows for a less burdensome approach to glucose monitoring. It has also completed four animal studies with evolving prototype systems, all four of which consistently demonstrated a simple implant procedure, functionality, and safety. The Company has also demonstrated continuous glucose sensing in the epidural space via two additional animal trials, both of which demonstrated a simple implant procedure, functionality, and safety.
公司代碼GCTK
公司GlucoTrack Inc
CEOGoode (Paul V)
網址https://glucotrack.com/
KeyAI